SG11201408419QA - Method for preparing substituted triazolopyridines - Google Patents
Method for preparing substituted triazolopyridinesInfo
- Publication number
- SG11201408419QA SG11201408419QA SG11201408419QA SG11201408419QA SG11201408419QA SG 11201408419Q A SG11201408419Q A SG 11201408419QA SG 11201408419Q A SG11201408419Q A SG 11201408419QA SG 11201408419Q A SG11201408419Q A SG 11201408419QA SG 11201408419Q A SG11201408419Q A SG 11201408419QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- str
- preparing substituted
- monheim
- english
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12175640 | 2012-07-10 | ||
| EP12185590 | 2012-09-24 | ||
| EP13170585 | 2013-06-05 | ||
| PCT/EP2013/064017 WO2014009219A1 (en) | 2012-07-10 | 2013-07-03 | Method for preparing substituted triazolopyridines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408419QA true SG11201408419QA (en) | 2015-01-29 |
Family
ID=48793197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408419QA SG11201408419QA (en) | 2012-07-10 | 2013-07-03 | Method for preparing substituted triazolopyridines |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9388177B2 (zh) |
| EP (1) | EP2872506A1 (zh) |
| JP (1) | JP6238979B2 (zh) |
| KR (1) | KR20150040845A (zh) |
| CN (1) | CN104603136B (zh) |
| AP (1) | AP3778A (zh) |
| AU (1) | AU2013289381A1 (zh) |
| BR (1) | BR112015000308A2 (zh) |
| CA (1) | CA2878481A1 (zh) |
| CL (1) | CL2015000038A1 (zh) |
| CO (1) | CO7160002A2 (zh) |
| CR (1) | CR20150006A (zh) |
| DO (1) | DOP2015000007A (zh) |
| EA (1) | EA027544B1 (zh) |
| HK (1) | HK1206731A1 (zh) |
| IL (1) | IL236265A (zh) |
| IN (1) | IN2015DN00085A (zh) |
| MX (1) | MX2015000348A (zh) |
| NZ (1) | NZ703020A (zh) |
| PE (1) | PE20150354A1 (zh) |
| PH (1) | PH12015500061A1 (zh) |
| SG (1) | SG11201408419QA (zh) |
| TN (1) | TN2015000008A1 (zh) |
| WO (1) | WO2014009219A1 (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2914521A1 (en) * | 2013-06-07 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | Substituted triazolopyridines having activity as mps-1 inhibitors |
| AP2015008898A0 (en) * | 2013-06-11 | 2015-12-31 | Bayer Pharma AG | Prodrug derivatives of substituted triazolopyridines |
| CA2914742A1 (en) | 2013-06-11 | 2014-12-18 | Bayer Pharma Aktiengesellschaft | Handovers with co-operating cells configured to provide coordinated multi-point transmission/reception |
| PL3283642T3 (pl) | 2015-04-17 | 2024-04-22 | Crossfire Oncology Holding B.V. | Biomarkery prognostyczne dla chemioterapii inhibitorem TTK |
| TW201800408A (zh) | 2016-06-15 | 2018-01-01 | 拜耳製藥公司 | Mps-1抑制劑 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1438973A4 (en) * | 2001-10-05 | 2005-07-13 | Ono Pharmaceutical Co | MEANS FOR THE TREATMENT OF STRESS-RELATED DISEASES WITH MITOCHONDRIENE BENZODIAZEPINE RECEPTOR ANTAGONISTS |
| US20060074102A1 (en) * | 2004-05-14 | 2006-04-06 | Kevin Cusack | Kinase inhibitors as therapeutic agents |
| UA89503C2 (uk) * | 2004-09-13 | 2010-02-10 | Х. Луннбек А/С | Заміщені похідні аніліну |
| MX2007004179A (es) * | 2004-10-07 | 2007-06-07 | Warner Lambert Co | Derivados de triazolpiridina como agentes antibacterianos. |
| US20060194823A1 (en) * | 2004-12-22 | 2006-08-31 | Georg Kettschau | Sulfonamido-macrocycles as Tie2 inhibitors and the salts thereof, a pharmaceutical composition comprising these compounds, the method of preparing and the use thereof |
| MX2008015747A (es) * | 2006-06-06 | 2008-12-19 | Schering Corp | Imidazopirazinas como inhibidores de la proteina quinasa. |
| EP1870416A1 (en) * | 2006-06-21 | 2007-12-26 | Bayer Schering Pharma Aktiengesellschaft | Sulphonamido-macrocycles as tie2 inhibitors |
| CN103641829A (zh) | 2006-08-30 | 2014-03-19 | 塞尔佐姆有限公司 | 作为激酶抑制剂的三唑衍生物 |
| JO3598B1 (ar) * | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| AU2008277628B2 (en) | 2007-07-18 | 2012-03-15 | Novartis Ag | Bicyclic heteroaryl compounds and their use as kinase inhibitors |
| BRPI0815709A2 (pt) | 2007-08-23 | 2017-06-13 | Astrazeneca Ab | composro, composição farmacêutica, e, uso de um composto. |
| CA2691448A1 (en) | 2007-08-31 | 2009-03-05 | Dominique Swinnen | Triazolopyridine compounds and their use as ask inhibitors |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB0724342D0 (en) * | 2007-12-13 | 2008-01-30 | Prolysis Ltd | Anitbacterial compositions |
| US8530689B2 (en) * | 2008-05-05 | 2013-09-10 | The Trustees Of The University Of Pennsylvania | Processes for the preparation of biphenyl compounds |
| EP2303890A4 (en) * | 2008-06-19 | 2012-04-11 | Progenics Pharm Inc | INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE |
| CA2751517A1 (en) | 2009-02-13 | 2010-08-19 | Fovea Pharmaceuticals | [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors |
| CN102413831B (zh) | 2009-04-29 | 2014-06-04 | 拜耳知识产权有限责任公司 | 取代的咪唑并喹喔啉 |
| TWI500614B (zh) * | 2009-06-05 | 2015-09-21 | Cephalon Inc | １，２，４－三唑並〔１，５ａ〕吡啶衍生物之製備和用途 |
| WO2010141360A1 (en) * | 2009-06-05 | 2010-12-09 | Merck Sharp & Dohme Corp. | Biaryl benzotriazole derivatives |
| CA2772790C (en) | 2009-09-04 | 2017-06-27 | Benjamin Bader | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
| EP2343294A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
| EP2343297A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| EP2343295A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridine derivates |
| UY33452A (es) * | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
| WO2012044567A2 (en) * | 2010-09-30 | 2012-04-05 | Merck Sharp & Dohme Corp. | Imidazole derivatives |
| PT2699575E (pt) * | 2011-04-21 | 2015-07-29 | Bayer Ip Gmbh | Triazolopiridinas |
| WO2012160029A1 (en) * | 2011-05-23 | 2012-11-29 | Bayer Intellectual Property Gmbh | Substituted triazolopyridines |
| UA112096C2 (uk) * | 2011-12-12 | 2016-07-25 | Байєр Інтеллектуал Проперті Гмбх | Заміщені триазолопіридини та їх застосування як інгібіторів ttk |
-
2013
- 2013-07-03 WO PCT/EP2013/064017 patent/WO2014009219A1/en active Application Filing
- 2013-07-03 JP JP2015520907A patent/JP6238979B2/ja not_active Expired - Fee Related
- 2013-07-03 US US14/414,164 patent/US9388177B2/en not_active Expired - Fee Related
- 2013-07-03 CA CA2878481A patent/CA2878481A1/en not_active Abandoned
- 2013-07-03 CN CN201380045913.9A patent/CN104603136B/zh not_active Expired - Fee Related
- 2013-07-03 EP EP13737181.1A patent/EP2872506A1/en not_active Withdrawn
- 2013-07-03 SG SG11201408419QA patent/SG11201408419QA/en unknown
- 2013-07-03 NZ NZ703020A patent/NZ703020A/en not_active IP Right Cessation
- 2013-07-03 BR BR112015000308A patent/BR112015000308A2/pt not_active IP Right Cessation
- 2013-07-03 PE PE2015000017A patent/PE20150354A1/es not_active Application Discontinuation
- 2013-07-03 EA EA201590116A patent/EA027544B1/ru not_active IP Right Cessation
- 2013-07-03 AP AP2014008177A patent/AP3778A/en active
- 2013-07-03 IN IN85DEN2015 patent/IN2015DN00085A/en unknown
- 2013-07-03 MX MX2015000348A patent/MX2015000348A/es unknown
- 2013-07-03 AU AU2013289381A patent/AU2013289381A1/en not_active Abandoned
- 2013-07-03 KR KR20157000338A patent/KR20150040845A/ko not_active Application Discontinuation
-
2014
- 2014-12-15 IL IL236265A patent/IL236265A/en not_active IP Right Cessation
-
2015
- 2015-01-07 TN TNP2015000008A patent/TN2015000008A1/fr unknown
- 2015-01-08 CL CL2015000038A patent/CL2015000038A1/es unknown
- 2015-01-09 CR CR20150006A patent/CR20150006A/es unknown
- 2015-01-09 CO CO15004251A patent/CO7160002A2/es unknown
- 2015-01-09 DO DO2015000007A patent/DOP2015000007A/es unknown
- 2015-01-09 PH PH12015500061A patent/PH12015500061A1/en unknown
- 2015-07-29 HK HK15107242.4A patent/HK1206731A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9388177B2 (en) | 2016-07-12 |
| EA201590116A1 (ru) | 2015-07-30 |
| TN2015000008A1 (en) | 2016-06-29 |
| DOP2015000007A (es) | 2015-02-15 |
| HK1206731A1 (zh) | 2016-01-15 |
| CO7160002A2 (es) | 2015-01-15 |
| IL236265A0 (en) | 2015-02-26 |
| PH12015500061A1 (en) | 2015-03-02 |
| US20150148542A1 (en) | 2015-05-28 |
| AP3778A (en) | 2016-08-31 |
| NZ703020A (en) | 2017-08-25 |
| BR112015000308A2 (pt) | 2017-06-27 |
| KR20150040845A (ko) | 2015-04-15 |
| IL236265A (en) | 2017-07-31 |
| CR20150006A (es) | 2015-02-16 |
| AP2014008177A0 (en) | 2014-12-31 |
| AU2013289381A1 (en) | 2015-01-22 |
| CN104603136B (zh) | 2017-06-27 |
| WO2014009219A1 (en) | 2014-01-16 |
| CA2878481A1 (en) | 2014-01-16 |
| CL2015000038A1 (es) | 2015-03-13 |
| IN2015DN00085A (zh) | 2015-05-29 |
| EA027544B1 (ru) | 2017-08-31 |
| EP2872506A1 (en) | 2015-05-20 |
| JP6238979B2 (ja) | 2017-11-29 |
| JP2015523372A (ja) | 2015-08-13 |
| MX2015000348A (es) | 2015-04-14 |
| CN104603136A (zh) | 2015-05-06 |
| PE20150354A1 (es) | 2015-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201408261UA (en) | Syringe | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201407417VA (en) | Encoding and reconstruction of residual data based on support information | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
| SG11201407037UA (en) | Catechol o-methyltransferase activity inhibiting compounds | |
| SG11201407596TA (en) | Conjugation reagents | |
| SG11201402986RA (en) | Kinase inhibitors | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea | |
| SG11201406787TA (en) | Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies | |
| SG11201407345QA (en) | Pyrazole compounds as sglt1 inhibitors | |
| SG11201811671XA (en) | Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof | |
| SG11201408419QA (en) | Method for preparing substituted triazolopyridines | |
| SG11201408502XA (en) | Method of purifying an antibody | |
| SG11201804048WA (en) | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic | |
| SG11201406745VA (en) | Methods of therapeutic monitoring of phenylacetic acid prodrugs |